8results about How to "Reduce pathological damage" patented technology

This invention relates to the field of traditional Chinese medicine technology, and more particularly to the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of lung injury. The traditional Chinese medicine composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that this traditional Chinese medicine composition can significantly reduce the level of the inflammatory factor TNF-α, decrease the lung index, and alleviate pathological damage to lung tissue, and can be used for the prevention and treatment of lung injury.

This application discloses the use of itaconic acid derivatives in the preparation of drugs for treating candidemia, belonging to the field of biomedical technology. The itaconic acid derivatives proposed in this application are dimethyl itaconic acid and / or 4-octyl itaconic acid. Dimethyl itaconic acid exhibits a dose-dependent therapeutic effect in model mice, with an optimal dose of 1200 mg / kg improving survival rate and reducing kidney damage; 4-octyl itaconic acid can enhance the anti-Candida albicans ability of macrophages and regulate the expression of inflammatory factors. The application of the itaconic acid derivatives proposed in this application in the treatment of candidemia works through immunomodulation, circumventing fungal resistance. Furthermore, the drugs are low in toxicity, have good biocompatibility, and use a universal experimental system, providing a new approach for the clinical treatment of candidemia with broad application prospects. This application also protects pharmaceutical compositions for treating candidemia with dimethyl itaconic acid and / or 4-octyl itaconic acid as active ingredients.

This invention relates to mitochondrial-enriched extracellular vesicles, their preparation methods, and applications, which can effectively solve the drug problem in spontaneous intracerebral hemorrhage. The technical solution involves using platelets as raw material, and obtaining platelet-derived extracellular vesicles carrying active mitochondria through activation induction, differential centrifugation and fractionation, membrane filtration and elution enrichment. This achieves efficient and stable loading of functional mitochondria, and the resulting PEV Mito has a complete structure and uniform particle size, which can effectively maintain mitochondrial membrane potential and biological activity. It can achieve efficient delivery and intracellular internalization to damaged neurons and restore mitochondrial function. The PEV Mito prepared by this invention has high delivery efficiency and excellent biocompatibility, and can be used to prepare drugs for the treatment of intracerebral hemorrhage and secondary neurological injury, with good prospects for clinical translation.

The application provides application of tanshinone or a derivative thereof in preparation of a monkeypox virus resisting drug. In a cell model infected by the monkeypox virus, production of infectious virus particles can be significantly reduced. In a mouse infection model, Tanshinone VII can effectively reduce pathological damage of lung tissues and improve survival rate of animals. The above evidence indicates that Tanshinone VII has potential efficacy in resisting the monkeypox virus. It is inferred that tanshinone or the derivative thereof can play a double role in resisting the monkeypox virus and host protection.

This invention discloses the application of the small molecule compound Z2114502286 in the preparation of drugs for the prevention and treatment of liver-related diseases. This invention reveals for the first time that Z2114502286 is a THBS2-specific small molecule inhibitor and verifies its feasibility in preventing and treating liver fibrosis by targeting and inhibiting the THBS2 protein. Through virtual screening and molecular docking, this compound can directly bind to the THBS2 protein. In vitro and in vivo studies show that this compound inhibits THBS2-mediated HSC activation in a concentration- and time-dependent manner, inhibits ECM deposition in a mouse model of liver fibrosis, downregulates the expression of fibrosis-related genes, and alleviates liver inflammation and macrophage infiltration. Simultaneously, the targeted efficacy was verified in a transgenic mouse model specifically expressing human THBS2, demonstrating significant clinical translational value. Furthermore, it exhibits bioavailability and safety at effective dosages, showing broad clinical application prospects.

This invention discloses a porcine reproductive and respiratory syndrome virus (PRRSV) mRNA molecule and its applications. Four mRNA vaccines, GP35m-LNP, GP45m-LNP, GP345m-LNP, and GP2345m-LNP, were designed by combining the NADC30-like structural proteins GP2a, GP3, GP4, and GP5 of the PRRSV FJ1402 strain. Mouse experiments showed that GP345m-LNP induced both strong humoral and cellular immune responses, followed by GP2345m-LNP, with better efficacy than the inactivated vaccine (which only induced humoral immunity). After immunization, challenge with the PRRSV FJ1402 strain resulted in significantly reduced viral load in the blood and lungs of the GP345m-LNP group, with significantly less pathological damage to the lungs. The immunization effect was superior to the inactivated vaccine group, demonstrating promising application prospects.

The application belongs to the field of clinical drug toxic side effects, and particularly relates to the use of phenazine-1-carboxylic acid in treating cisplatin-mediated acute kidney injury. The application first discovers and proves that phenazine-1-carboxylic acid can effectively alleviate cisplatin-induced acute kidney injury. In a cisplatin-induced acute kidney injury model of mice, intraperitoneal injection of phenazine-1-carboxylic acid can effectively protect kidney function, which is specifically manifested as follows: significantly reducing urea nitrogen and creatinine levels in serum of model mice; reducing pathological injury of kidney tissue and reducing tubular injury score; and inhibiting expression of inflammatory factors and injury markers in kidney tissue. The treatment effect is equivalent to that of a classic ferroptosis inhibitor, Ferrostatin-1, and a new candidate drug for solving the dose-limiting toxicity of cisplatin in clinical application is provided.

The application discloses lactobacillus plantarum WH021 and application thereof in prevention and / or alleviation of neuroinflammation, and belongs to the technical field of microorganisms. The lactobacillus plantarum WH021 is obtained by separation and purification from healthy infant feces, is a probiotic with the effect of alleviating neuroinflammation, and has good application potential in development of food, health products and drugs for preventing brain inflammation related diseases of middle-aged and old people caused by chronic inflammation of the body.